Skip to main content

Table 2 Fatigue in the Nordic JIA cohort according to clinical characteristics at 18-year follow-up

From: Fatigue in young adults with juvenile idiopathic arthritis 18 years after disease onset: data from the prospective Nordic JIA cohort

    Severe fatigueb  
No. assessed Fatiguea mean ±SD No. (%) OR (95% CI) crude p-value OR (95% CI) adjustedc p-value VAS fatigued mean ±SD
Norwegian controls 109 2.8 ±1.1 13 (12) 1.0 (ref.) 1.0 (ref.) 2.5 ±2.3
Total Nordic JIA cohort 377 3.2 ±1.5 99 (26) 2.6 (1.4–4.9) 0.002 2.7 (1.4–5.1) 0.002 3.8 ±2.7h
Sleep qualitye
 Good sleep, PSQI ≤5 213 2.7 ±1.2 32 (15) 1.0 (ref.) 1.0 (ref.) 2.8 ±2.5
 Poor sleep, PSQI > 5 158 3.9 ±1.4 66 (42) 4.1 (2.5–6.6) < 0.001 3.7 (2.2–6.1) < 0.001 5.3 ±2.4
VAS pain
 0 153 2.6 ±1.1 20 (13) 1.0 (ref.) 1.0 (ref.) 2.9 ±2.6h
 > 0 217 3.7 ±1.5 79 (36) 3.8 (2.2–6.6) < 0.001 3.7 (2.1–6.5) < 0.001 4.5 ±2.7
Participation in work/study
 Full 301 3.0 ±1.3 64 (21) 1.0 (ref.) 1.0 (ref.) 3.6 ±2.6h
 Partial 33 4.0 ±1.7 15 (45) 3.1 (1.5–6.5) 0.003 2.8 (1.3–6.0) 0.008 4.1 ±2.9
 No 38 4.0 ±1.8 19 (50) 3.7 (1.9–7.4) < 0.001 3.5 (1.7–7.3) 0.001 5.1 ±3.1
SF-36
 PCS ≥40 322 3.0 ±1.3 64 (20) 1.0 (ref.) 1.0 (ref.) 3.4 ±2.6h
 PCS < 40 55 4.7 ±1.6 35 (64) 7.1 (3.8–13.0) < 0.001 6.2 (3.3–11.8) < 0.001 6.2 ±2.4
 MCS ≥40 310 2.9 ±1.3 58 (19) 1.0 (ref.) 1.0 (ref.) 3.3 ±2.6h
 MCS < 40 67 4.6 ±1.5 41 (61) 6.9 (3.9–12.1) < 0.001 7.1 (3.9–13.0) < 0.001 6.5 ±1.9
HAQ
 =0 260 2.8 ±1.3 47 (18) 1.0 (ref.) 1.0 (ref.) 3.2 ±2.5h
 > 0 110 4.1 ±1.6 52 (47) 4.1 (2.5–6.6) < 0.001 3.7 (2.2–6.1) < 0.001 5.4 ±2.7
Disease statusf
 Remission off med. 112 2.9 ±1.4 21 (19) 1.0 (ref.) 1.0 (ref.) 3.2 ±2.7h
 Inactive disease 75 3.2 ±1.5 22 (29) 1.8 (0.9–3.6) 0.09 2.0 (1.0–4.1) 0.06 3.7 ±2.7
 Active disease 121 3.6 ±1.6 43 (36) 2.4 (1.3–4.4) 0.005 2.2 (1.2–4.2) 0.01 4.4 ±2.8
 Not ascertainedg 61 3.1 ±1.3 12 (20) 1.0 (0.5–2.3) 0.9 1.0 (0.4–2.2) 1.0 4.3 ±2.5
  1. JIA juvenile idiopathic arthritis, No. numbers, SD standard deviation, OR odds ratio for Fatigue Severity Scale ≥4, CI confidence interval, ref. reference, VAS pain self-reported pain measured on a 21-numbered circle visual analogue scale (0 = no pain, 10 = maximum pain), SF-36 36-Item Short Form Health Survey, 0–100 (< 40 poor health), PCS physical component summary, MCS mental component summary, HAQ Health Assessment Questionnaire, 0–3 (0 = lowest, 3 = highest)
  2. aFatigue measured with Fatigue Severity Scale global score, 1–7 (1 = lowest, 7 = highest)
  3. bFatigue Severity Scale ≥4
  4. cAdjusted for age and sex
  5. dFatigue Severity Scale visual analogue scale, 21-numbered circle VAS (0 = no fatigue, 10 = maximum fatigue)
  6. eSleep quality measured with Pittsburgh Sleep Quality Index global score (PSQI), 0–21 (0 = best, 21 = worst)
  7. fAccording to the definition by Wallace et al.; Remission off med. = remission off medication for ≥12 months. Inactive disease = inactive disease on medication less than 6 months or inactive disease off medication less than 12 months or remission on medication (inactive disease on medication for more than 6 months). Active disease = flare or continuous active disease
  8. gNot ascertained = participated only in a telephone interview
  9. h1 of 377 participants did not fill in VAS fatigue